|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao H, Sun Z, Wu J, Hao C and Wang W:
Metastatic clear cell renal cell carcinoma to pancreas and distant
organs 24 years after radical nephrectomy: A case report and
literature review. Front Surg. 9:8942722022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bai C, Sen P, Hofmann K, Ma L, Goebl M,
Harper JW and Elledge SJ: SKP1 connects cell cycle regulators to
the ubiquitin proteolysis machinery through a novel motif, the
F-box. Cell. 86:263–274. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nguyen KM and Busino L: The biology of
F-box proteins: The SCF family of E3 ubiquitin ligases. Adv Exp Med
Biol. 1217:111–122. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shen W, Zhou Q, Peng C, Li J, Yuan Q, Zhu
H, Zhao M, Jiang X, Liu W and Ren C: FBXW7 and the hallmarks of
cancer: Underlying mechanisms and prospective strategies. Front
Oncol. 12:8800772022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu H, Wang X, Zhou X, Lu S, Gu G and Liu
C: E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small
cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A
through ubiquitination. Lab Invest. 102:1203–1213. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nita A, Nishiyama M, Muto Y and Nakayama
KI: FBXL12 regulates T-cell differentiation in a cell-autonomous
manner. Genes Cells. 21:517–524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watanabe K, Yumimoto K and Nakayama KI:
FBXO21 mediates the ubiquitylation and proteasomal degradation of
EID1. Genes Cells. 20:667–674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li D, Xie P, Zhao F, Shu J, Li L, Zhan Y
and Zhang L: F-box protein Fbxo3 targets Smurf1 ubiquitin ligase
for ubiquitination and degradation. Biochem Biophys Res Commun.
458:941–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tekcham DS, Chen D, Liu Y, Ling T, Zhang
Y, Chen H, Wang W, Otkur W, Qi H, Xia T, et al: F-box proteins and
cancer: An update from functional and regulatory mechanism to
therapeutic clinical prospects. Theranostics. 10:4150–4167. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sartori R, Schirwis E, Blaauw B,
Bortolanza S, Zhao J, Enzo E, Stantzou A, Mouisel E, Toniolo L,
Ferry A, et al: BMP signaling controls muscle mass. Nat Genet.
45:1309–1318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin Y, Yang M, Gao C, Yue W, Liang X, Xie
B, Zhu X, Fan S, Li R and Li M: Fbxo30 regulates chromosome
segregation of oocyte meiosis. Cell Mol Life Sci. 76:2217–2229.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng X, Pei P, Yu J, Zhang Q, Li D, Xie
X, Wu J, Wang S and Zhang T: F-box protein FBXO30 mediates retinoic
acid receptor γ ubiquitination and regulates BMP signaling in
neural tube defects. Cell Death Dis. 10:5512019. View Article : Google Scholar
|
|
16
|
Bjerre MT, Strand SH, Nørgaard M,
Kristensen H, Rasmussen AK, Mortensen MM, Fredsøe J, Mouritzen P,
Ulhøi B, Ørntoft T, et al: Aberrant DOCK2, GRASP, HIF3A and PKFP
hypermethylation has potential as a prognostic biomarker for
prostate cancer. Int J Mol Sci. 20:11732019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bjerre MT, Nørgaard M, Larsen OH, Jensen
SØ, Strand SH, Østergren P, Fode M, Fredsøe J, Ulhøi BP, Mortensen
MM, et al: Epigenetic analysis of circulating tumor DNA in
localized and metastatic prostate cancer: Evaluation of clinical
biomarker potential. Cells. 9:13622020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiong W, Zeng ZY, Shen SR, Li XL, Li WF,
Wang R, Xiong F, Peng C, Zhang QH, Zhou M, et al: Studies on the
relationship between D6S1581, a high frequency allele imbalance
locus, and genetic susceptibility to nasopharyngeal carcinoma.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 20:311–314. 2003.In
Chinese.
|
|
19
|
Pezzuto A and Carico E: Role of HIF-1 in
cancer progression: Novel insights. A review. Curr Mol Med.
18:343–351. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li JN, Chen PS, Chiu CF, Lyu YJ, Lo C,
Tsai LW and Wang MY: TARBP2 suppresses ubiquitin-proteasomal
degradation of HIF-1α in breast cancer. Int J Mol Sci. 23:2082021.
View Article : Google Scholar
|
|
21
|
Liu J, Zhang C, Zhao Y, Yue X, Wu H, Huang
S, Chen J, Tomsky K, Xie H, Khella CA, et al: Parkin targets HIF-1α
for ubiquitination and degradation to inhibit breast tumor
progression. Nat Commun. 8:18232017. View Article : Google Scholar
|
|
22
|
Flügel D, Görlach A and Kietzmann T:
GSK-3β regulates cell growth, migration, and angiogenesis via Fbw7
and USP28-dependent degradation of HIF-1α. Blood. 119:1292–1301.
2012. View Article : Google Scholar
|
|
23
|
Bowers K and Srai SKS: The trafficking of
metal ion transporters of the Zrt- and Irt-like protein family.
Traffic. 19:813–822. 2018. View Article : Google Scholar
|
|
24
|
Costello LC and Franklin RB: A
comprehensive review of the role of zinc in normal prostate
function and metabolism; and its implications in prostate cancer.
Arch Biochem Biophys. 611:100–112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jeong J and Eide DJ: The SLC39 family of
zinc transporters. Mol Aspects Med. 34:612–619. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dineley KE, Votyakova TV and Reynolds IJ:
Zinc inhibition of cellular energy production: Implications for
mitochondria and neurodegeneration. J Neurochem. 85:563–570. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong X, Kong C, Zhang Z, Liu X, Zhan B,
Chen Z and Shi D: hZIP1 that is down-regulated in clear cell renal
cell carcinoma is negatively associated with the malignant
potential of the tumor. Urol Oncol. 32:885–892. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhan B, Dong X, Yuan Y, Gong Z and Li B:
hZIP1 inhibits progression of clear cell renal cell carcinoma by
suppressing NF-kB/HIF-1α pathway. Front Oncol. 11:7598182021.
View Article : Google Scholar
|
|
29
|
Delahunt B, Eble JN, Egevad L and
Samaratunga H: Grading of renal cell carcinoma. Histopathology.
74:4–17. 2019. View Article : Google Scholar
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
31
|
Ma X, Li C, Sun L, Huang D, Li T, He X, Wu
G, Yang Z, Zhong X, Song L, et al: Lin28/let-7 axis regulates
aerobic glycolysis and cancer progression via PDK1. Nat Commun.
5:52122014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park JS, Lee ME, Kim SH, Jang WS and Ham
WS: Development of a highly pulmonary metastatic orthotopic renal
cell carcinoma murine model. Biol Open. 10:bio0585662021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schödel J, Grampp S, Maher ER, Moch H,
Ratcliffe PJ, Russo P and Mole DR: Hypoxia, hypoxia-inducible
transcription factors, and renal cancer. Eur Urol. 69:646–657.
2016. View Article : Google Scholar :
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wigerup C, Påhlman S and Bexell D:
Therapeutic targeting of hypoxia and hypoxia-inducible factors in
cancer. Pharmacol Ther. 164:152–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Choi WSW, Boland J and Lin J:
Hypoxia-inducible factor-2α as a novel target in renal cell
carcinoma. J Kidney Cancer VHL. 8:1–7. 2021. View Article : Google Scholar :
|
|
36
|
Rashid M, Zadeh LR, Baradaran B, Molavi O,
Ghesmati Z, Sabzichi M and Ramezani F: Up-down regulation of HIF-1α
in cancer progression. Gene. 798:1457962021. View Article : Google Scholar
|
|
37
|
Doonachar A, Gallo MD, Doukas D, Pasricha
R, Lantsberg I and Schoenfeld AR: Differential effects of HIF-α
isoforms on apoptosis in renal carcinoma cell lines. Cancer Cell
Int. 15:232015. View Article : Google Scholar
|
|
38
|
Hoefflin R, Harlander S, Schäfer S,
Metzger P, Kuo F, Schönenberger D, Adlesic M, Peighambari A, Seidel
P, Chen CY, et al: HIF-1α and HIF-2α differently regulate tumour
development and inflammation of clear cell renal cell carcinoma in
mice. Nat Commun. 11:41112020. View Article : Google Scholar
|
|
39
|
Chen N, Kong X, Zhao S and Xiaofeng W:
Post-translational modification of baculovirus-encoded proteins.
Virus Res. 279:1978652020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morishita Y, Ookawara S, Hirahara I, Muto
S and Nagata D: HIF-1α mediates hypoxia-induced
epithelial-mesenchymal transition in peritoneal mesothelial cells.
Ren Fail. 38:282–289. 2016. View Article : Google Scholar
|
|
41
|
Das B, Tsuchida R, Malkin D, Koren G,
Baruchel S and Yeger H: Hypoxia enhances tumor stemness by
increasing the invasive and tumorigenic side population fraction.
Stem Cells. 26:1818–1830. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ide T, Kitajima Y, Miyoshi A, Ohtsuka T,
Mitsuno M, Ohtaka K, Koga Y and Miyazaki K: Tumor-stromal cell
interaction under hypoxia increases the invasiveness of pancreatic
cancer cells through the hepatocyte growth factor/c-Met pathway.
Int J Cancer. 119:2750–2759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Skrajnowska D and Bobrowska-Korczak B:
Role of zinc in immune system and anti-cancer defense mechanisms.
Nutrients. 11:22732019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
To PK, Do MH, Cho JH and Jung C: Growth
modulatory role of zinc in prostate cancer and application to
cancer therapeutics. Int J Mol Sci. 21:29912020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gelbard A: Zinc in cancer therapy
revisited. Isr Med Assoc J. 24:258–262. 2022.PubMed/NCBI
|
|
46
|
Liu L, Hou Y, Hu J, Zhou L, Chen K, Yang X
and Song Z: SLC39A8/zinc suppresses the progression of clear cell
renal cell carcinoma. Front Oncol. 11:6519212021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nardinocchi L, Pantisano V, Puca R, Porru
M, Aiello A, Grasselli A, Leonetti C, Safran M, Rechavi G, Givol D,
et al: Zinc downregulates HIF-1α and inhibits its activity in tumor
cells in vitro and in vivo. PLoS One. 5:e150482010. View Article : Google Scholar
|
|
48
|
Olechnowicz J, Tinkov A, Skalny A and
Suliburska J: Zinc status is associated with inflammation,
oxidative stress, lipid, and glucose metabolism. J Physiol Sci.
68:19–31. 2018. View Article : Google Scholar :
|
|
49
|
Kierans SJ and Taylor CT: Regulation of
glycolysis by the hypoxia-inducible factor (HIF): Implications for
cellular physiology. J Physiol. 599:23–37. 2021. View Article : Google Scholar
|
|
50
|
Chakraborty S, Balan M, Sabarwal A,
Choueiri TK and Pal S: Metabolic reprogramming in renal cancer:
Events of a metabolic disease. Biochim Biophys Acta Rev Cancer.
1876:1885592021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wise DR and Thompson CB: Glutamine
addiction: A new therapeutic target in cancer. Trends Biochem Sci.
35:427–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lai Y, Tang F, Huang Y, He C, Chen C, Zhao
J, Wu W and He Z: The tumour microenvironment and metabolism in
renal cell carcinoma targeted or immune therapy. J Cell Physiol.
236:1616–1627. 2021. View Article : Google Scholar
|
|
53
|
Li F, Aljahdali IAM, Zhang R, Nastiuk KL,
Krolewski JJ and Ling X: Kidney cancer biomarkers and targets for
therapeutics: Survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2,
MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J Exp Clin
Cancer Res. 40:2542021. View Article : Google Scholar
|
